The U.S. Food and Drug Administration (FDA) has cleared medical imaging software developer SyntheticMR's SyMRI Neuro software.
The software measures the tissue properties of the brain and provides quantitative data, automatic segmentation, and adjustable contrast images to aid diagnosis and follow-up, according to the firm. In particular, SyMRI Neuro includes measurements and segmentation of myelin volumes, which may be useful for monitoring patients with neurodegenerative disorders such as multiple sclerosis and dementia.
Initially the clearance is attached to MR cameras from GE Healthcare, SyntheticMR said.
